• Morgan Stanley upgraded Cytokinetics, Incorporated (NASDAQ:CYTK) to Overweight with a price target increase from $65 to $71 following FDA approval of Myqorzo.
• Myqorzo, designed for symptomatic obstructive hypertrophic cardiomyopathy (oHCM), marks Cytokinetics' transition to a commercial-stage company.
• Cytokinetics' stock has seen a significant increase, with a 92.2% rise over the past six months, outperforming the industry's 25.7% gain.

Cytokinetics, Incorporated (NASDAQ:CYTK) is a biopharmaceutical company focused on discovering, developing, and commercializing muscle biology-driven treatments. The company has recently gained attention due to the U.S. Food and Drug Administration (FDA) approval of its drug Myqorzo (aficamten), designed to treat symptomatic obstructive hypertrophic cardiomyopathy (oHCM). This approval marks a significant milestone for Cytokinetics, transitioning it from a development-stage biotech to a commercial-stage entity.

On December 22, 2025, Morgan Stanley adjusted the grade of Cytokinetics to Overweight, maintaining a hold action. At the time, the stock price was approximately $68.46. Morgan Stanley also raised the price target for Cytokinetics from $65 to $71, as highlighted by TheFly. This adjustment reflects the positive outlook for the company following the FDA approval of Myqorzo.

The approval of Myqorzo is expected to provide a new therapeutic option for patients suffering from oHCM, highlighting Cytokinetics' commitment to advancing cardiovascular health. Myqorzo functions as an allosteric and reversible inhibitor of cardiac myosin motor activity, which helps reduce cardiac contractility and left ventricular outflow tract (LVOT) obstruction in patients with oHCM. However, it comes with a Boxed WARNING due to the risk of heart failure, necessitating regular echocardiogram assessments for patients.

The U.S. launch of Myqorzo is planned for early 2026, with regulatory progress also underway in Europe and China, positioning Cytokinetics for global expansion. Following the FDA approval announcement, Cytokinetics' shares have seen a significant increase, rising 92.2% over the past six months, compared to the industry's 25.7% gain. This FDA approval opens a long-term growth runway for Cytokinetics in the cardiology sector.

Currently, the stock for CYTK is priced at $67.36, reflecting an increase of 7.40% or $4.64. Today, the stock has fluctuated between a low of $63.18 and a high of $70.98, which also marks its highest price over the past year. The lowest price for the stock in the past year was $29.31. With a market capitalization of approximately $8.01 billion and a trading volume of 5,416,017 shares, Cytokinetics is well-positioned for future growth.